Disclosed is 6-methyl myristic acid monoglyceride derivative compounds having represented by structural formula (I), wherein the variables are defined in the specification. These compounds are suitable for the treatment of depressive mood disorder, anxiety disorder, irritable bowel syndrome, inflammatory bowel disease, inflammatory airway disease or urinary incontinence.
